Pfizer Confirms Successful Vaccine Trial With 90% Efficacy Against COVID-19
The American pharma company said that less than 10% of the infection was found in patients who were given the injection, which is currently in its phase three trials
American pharmaceutical giant Pfizer has claimed that their COVID-19 vaccine, currently in its phase three trials, has displayed a 90% efficacy in preventing the virus from infecting humans. The company partnered with the Germany based BioNTech to develop and manufacture the injection.
The analysis looked at the first 94 confirmed cases among more than the 43,000 volunteers, who got either two doses or even placebo. Less than 10% of the infections were found in the patients who were given the inoculation. According to preliminary investigations, protection from Coronavirus in the candidates was discovered in seven days post the administration of the second of the double-shot immunisation and in 28 days after the first dose.
In a statement issued by Pfizer Chairman and Chief Executive officer (CEO) Albert Bourla, the first set of results from the company’s phase three trials provides initial evidence of the injection’s ability to prevent COVID19. He further said that his team is significantly closer to providing people around the world with the much-needed breakthrough to end the global health crisis.
For now, the management will push for an emergency use authorisation from the United States Food and Drug Administration (FDA). It aims to supply 50 million doses across the world in 2020 and 1.3 billion vaccines in 2021.
Watch all the latest trending news only on ZEE5